Overview

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Status:
Not yet recruiting
Trial end date:
2024-05-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of tozorakimab as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen on the prevention of death or progression to IMV/ECMO.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca